Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NIB103
i
Other names:
NIB103, TAK-103, NIB-103
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Noile-Immune Biotech
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
‹
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
SynKIR-110 (1)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
UCLM802 (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
SynKIR-110 (1)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
UCLM802 (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
›
Associations
News
Trials
Filter by
Latest
11ms
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=2, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=21 --> 2
11 months ago
Enrollment closed • Enrollment change • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
over1year
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=21, Recruiting, Takeda | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
over 1 year ago
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
over2years
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=21, Recruiting, Takeda | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
almost3years
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=21, Not yet recruiting, Takeda
almost 3 years ago
New P1 trial
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login